BAXTER INTERNATIONAL INC 8-K

What Happened

• On July 14, 2026, Baxter International Inc. filed a Form 8-K (Regulation FD disclosure) announcing a change to its reportable segments effective for the quarter ended June 30, 2026 (Q2 2026). The company consolidated its prior three-segment view into two segments: Medical Products & Therapies (MPT) and Healthcare Systems & Technologies (HST). The former Pharmaceuticals segment is now included in the Infusion Therapies & Platforms (ITP) division of MPT.

Key Details

• Effective period: changes apply beginning with the quarter ended June 30, 2026 (Q2 2026).
• New segments and scope: MPT (Infusion Therapies & Platforms and Advanced Surgery) and HST (Front Line Care and Care & Connectivity Solutions).
• Recast financials: Baxter provided unaudited recast segment and product category results in Exhibit 99.1 for Q1 2026, the years ended Dec 31, 2025 and 2024, and each quarterly period in those years to aid comparability.
• No change to consolidated results: the recast is not a restatement and does not affect previously reported net income, EPS, total assets, or stockholders’ equity.
• Corporate allocation change: certain shared corporate expenses will now remain unallocated rather than being fully allocated to segments.
• Other reclassifications: sales previously reported in “Other” tied to certain manufacturing facilities for ITP are now reported in the ITP division; remaining “Other” sales mainly relate to Vantive Health LLC under the Kidney Care MSA. Signed by Anita A. Zielinski, Interim CFO.

Why It Matters

• For investors, the segmentation and corporate cost-allocation changes affect how you compare past and future segment revenues, margins, and profitability metrics. Baxter will provide comparative recast figures, but analysts should use the Exhibit 99.1 recast tables (and future updated disclosures) when evaluating segment trends. Consolidated financial performance is unchanged.